What is Opdivo?
Opdivo, also known as Nivolumab, is a medication used in the treatment of cancer. It is classified as an immune checkpoint inhibitor, which means that it helps to activate the body's immune system to fight cancer cells.
Opdivo is administered via intravenous injection and was first approved by the US Food and Drug Administration (FDA) in 2014 for the treatment of metastatic melanoma. Since then, it has been approved for use in several other cancer types, including advanced lung cancer, renal cell carcinoma, and Hodgkin's lymphoma.
While Opdivo can be effective in helping the body's immune system fight cancer, it is not without potential side effects. These can include fatigue, nausea, decreased appetite, skin rash, and diarrhea. In rare cases, more severe side effects such as inflammation of the lungs, liver, or kidneys, can occur.
It is important to work closely with a healthcare provider when taking Opdivo, as they can monitor for any potential side effects and adjust the treatment plan as necessary. Overall, Opdivo offers a promising option for those battling certain types of cancer, and ongoing research is exploring its potential use in additional cancer types and treatment settings.
Frequently Asked Questions about opdivo
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the lining of the urinary tract (including the bladder, ureters, or renal pelvis) [urothelial carcinoma] to help prevent cancer of the urinary tract from coming back after it was removed by surgery.
OPDIVO is a prescription medicine that may be used in adults to help prevent cancer of the tube that connects your throat to your stomach (esophageal cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) from coming back after it has been treated with chemoradiation followed by ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with metastatic non-small cell ...
Nivolumab is a type of cancer treatment drug called immunotherapy. It's a treatment for a number of different types of cancer. It's also known as Opdivo. Depending on your cancer type you might have nivolumab on its own or in combination with other anti cancer drugs.
Opdivo, Keytruda launches in India slated by end of 2016 | Fierce Pharma.
How does OPDIVO work? OPDIVO can bind to the PD-1 receptor on T cells and block the interaction with PD-L1/PD-L2. This prevents cancer cells from disguising themselves and allows your T cells to be active and attack cancer cells again.
Opdivo, Keytruda launches in India slated by end of 2016 | Fierce Pharma.
Intravenous Solution
| Quantity | Per unit | Price |
|---|
| 4 milliliters | $324.34 | $1,297.35 |
| 10 milliliters | $322.91 | $3,229.12 |
| 12 milliliters | $322.75 | $3,873.04 |
| 24 milliliters | $322.36 | $7,736.61 |
Ono and U.S. drugmaker Medarex started developing Opdivo, then called nivolumab, in 2005 using Honjo's identification of PD-1.
The cost for Opdivo intravenous solution (10 mg/mL) is around $1,297 for a supply of 4 milliliters, depending on the pharmacy you visit.
The cost for Opdivo intravenous solution (10 mg/mL) is around $1,297 for a supply of 4 milliliters, depending on the pharmacy you visit.
For patients receiving Opdivo plus Opdualag, the 12-, 24- and 36-month progression-free survival rates were 48%, 38% and 31%, respectively. Overall survival rates were 77%, 62% and 54%, at these time points, respectively, with a 48-month overall survival rate of 52%.
We're one of the largest housing providers in the UK and a member of the G15 group of London's largest housing associations. We've over 45,000 homes across London, the South East and the Midlands, giving 90,000 people somewhere affordable to call their own.
For patients receiving Opdivo plus Opdualag, the 12-, 24- and 36-month progression-free survival rates were 48%, 38% and 31%, respectively. Overall survival rates were 77%, 62% and 54%, at these time points, respectively, with a 48-month overall survival rate of 52%.
The active substance in Opdivo, nivolumab, is a monoclonal antibody, a type of protein that has been designed to attach to a receptor called PD-1 found on cells of the immune system called T cells.
On March 4, 2022, the FDA approved nivolumab (brand name Opdivo) with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting. This represents the first FDA approval for neoadjuvant therapy for early-stage non-small cell lung cancer.
